- Home
- SRTS vs RNXT Comparison
SRTS vs RNXT Comparison
Compare SRTS & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- RNXT
- Stock Information
- Founded
- SRTS 2010
- RNXT 2012
- Country
- SRTS United States
- RNXT United States
- Employees
- SRTS N/A
- RNXT N/A
- Industry
- SRTS Medical/Dental Instruments
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- RNXT Health Care
- Exchange
- SRTS Nasdaq
- RNXT Nasdaq
- Market Cap
- SRTS 51.8M
- RNXT 44.6M
- IPO Year
- SRTS 2016
- RNXT 2021
- Fundamental
- Price
- SRTS $3.15
- RNXT $1.26
- Analyst Decision
- SRTS Strong Buy
- RNXT Strong Buy
- Analyst Count
- SRTS 3
- RNXT 2
- Target Price
- SRTS $8.00
- RNXT $7.50
- AVG Volume (30 Days)
- SRTS 84.7K
- RNXT 648.4K
- Earning Date
- SRTS 11-13-2025
- RNXT 11-12-2025
- Dividend Yield
- SRTS N/A
- RNXT N/A
- EPS Growth
- SRTS N/A
- RNXT N/A
- EPS
- SRTS N/A
- RNXT N/A
- Revenue
- SRTS $37,564,000.00
- RNXT $662,000.00
- Revenue This Year
- SRTS N/A
- RNXT $2,895.35
- Revenue Next Year
- SRTS $46.14
- RNXT $313.04
- P/E Ratio
- SRTS N/A
- RNXT N/A
- Revenue Growth
- SRTS 3.29
- RNXT N/A
- 52 Week Low
- SRTS $3.03
- RNXT $0.75
- 52 Week High
- SRTS $9.33
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- SRTS 37.43
- RNXT 58.65
- Support Level
- SRTS $3.09
- RNXT $1.19
- Resistance Level
- SRTS $3.29
- RNXT $1.45
- Average True Range (ATR)
- SRTS 0.11
- RNXT 0.12
- MACD
- SRTS 0.04
- RNXT 0.02
- Stochastic Oscillator
- SRTS 15.38
- RNXT 62.75
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.